Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bio-Rad Laboratories, Inc. (BIO : NYSE)
 
 • Company Description   
Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories.

Number of Employees: 950

 
 • Price / Volume Information   
Yesterday's Closing Price: $514.36 Daily Weekly Monthly
20 Day Moving Average: 236,880 shares
Shares Outstanding: 29.94 (millions)
Market Capitalization: $15,400.76 (millions)
Beta: 0.93
52 Week High: $832.70
52 Week Low: $468.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.57% 0.87%
12 Week -11.76% -7.10%
Year To Date -31.92% -20.65%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1000 ALFRED NOBEL DRIVE
-
HERCULES,CA 94547
USA
ph: 510-724-7000
fax: 510-741-5817
investor_relations@bio-rad.com http://www.bio-rad.com
 
 • General Corporate Information   
Officers
Norman Schwartz - Chief Executive Officer and Chairman
Ilan Daskal - Senior Vice President and Chief Accounting Officer
Ajit Ramalingam - Senior Vice President and Chief Accounting Officer
Jeffrey L. Edwards - Director
Gregory K. Hinckley - Director

Peer Information
Bio-Rad Laboratories, Inc. (BJCT)
Bio-Rad Laboratories, Inc. (CADMQ)
Bio-Rad Laboratories, Inc. (APNO)
Bio-Rad Laboratories, Inc. (UPDC)
Bio-Rad Laboratories, Inc. (IMTIQ)
Bio-Rad Laboratories, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 090572207
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 29.94
Most Recent Split Date: 3.00 (2.00:1)
Beta: 0.93
Market Capitalization: $15,400.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $2.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $14.20 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 36.22
Trailing 12 Months: 33.40
PEG Ratio: -
Price Ratios
Price/Book: 1.51
Price/Cash Flow: 32.54
Price / Sales: 5.32
EPS Growth
vs. Year Ago Period: -5.18%
vs. Previous Quarter: 53.89%
Sales Growth
vs. Year Ago Period: -3.68%
vs. Previous Quarter: -4.46%
ROE
03/31/22 - 3.66
12/31/21 - 3.70
09/30/21 - 4.19
ROA
03/31/22 - 2.77
12/31/21 - 2.83
09/30/21 - 3.21
Current Ratio
03/31/22 - 5.10
12/31/21 - 2.92
09/30/21 - 3.79
Quick Ratio
03/31/22 - 4.16
12/31/21 - 2.08
09/30/21 - 2.89
Operating Margin
03/31/22 - 16.06
12/31/21 - 16.19
09/30/21 - 16.69
Net Margin
03/31/22 - -3.49
12/31/21 - 145.28
09/30/21 - 223.47
Pre-Tax Margin
03/31/22 - -7.95
12/31/21 - 186.08
09/30/21 - 287.11
Book Value
03/31/22 - 340.09
12/31/21 - 456.60
09/30/21 - 512.48
Inventory Turnover
03/31/22 - 2.12
12/31/21 - 2.17
09/30/21 - 2.12
Debt-to-Equity
03/31/22 - 0.12
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 10.52
12/31/21 - 0.08
09/30/21 - 0.07
 

Powered by Zacks Investment Research ©